Department of Biotechnology; and Department of Bio-molecular Engineering, Kyoto Institute of Technology, Kyoto 606-8585, Japan.
J Biochem. 2013 Dec;154(6):551-9. doi: 10.1093/jb/mvt086. Epub 2013 Sep 26.
Hereditary coproporphyria (HCP) is an autosomal dominant-inherited disease of haem biosynthesis caused by partial deficiency of the enzyme coproporphyrinogen oxidase (CPOX). Patients with HCP show <50% of normal activity and those with the rare autosomal recessive harderoporphyria accumulate harderoporphyrinogen, an intermediate porphyrin of the CPOX reaction. To clarify the relationship of the low enzyme activity with these diseases, we expressed mutant CPOX carrying His-tag from these porphyria patients and co-expressed mutant CPOX carrying His-tag and normal CPOX carrying HA-tag in a tandem fashion in Escherichia coli. Purification of the His-tag-containing enzyme revealed that the His-enzyme forms a heterodimer in association with the HA-enzyme, and analysis using a cross-link reagent confirmed that the enzyme is a dimer (∼70 kDa). Then, we expressed homo- and heterodimers composed of the wild-type (wt) and engineered mutants of the enzyme or mutants from HCP patients. The monomer form of mutated CPOX did not show any activity and homodimeric enzymes derived from HCP mutant showed low activity (<20% of the control). Some mutations of amino acids 401-404 were associated with marked accumulation of harderoporphyrinogen, with a decrease in the production of protoporphyrinogen, whereas K404E derived from patients with harderoporphyria produced less harderoporphyrinogen. The heterodimers with wt and mutated subunits from HCP patients showed low protoporphyrinogen producing activity. These results show that the substitution of amino acids from R401 to K404 results in extremely low enzyme activity with either mutant homodimer or heterodimers containing normal and mutated subunits and can be linked to HCP disease.
遗传性粪卟啉症(HCP)是一种常染色体显性遗传性血红素生物合成疾病,由粪卟啉原氧化酶(CPOX)部分缺乏引起。HCP 患者的酶活性<50%,而罕见的常染色体隐性遗传性硬卟啉症患者则会积累硬卟啉原,这是 CPOX 反应的中间卟啉。为了阐明低酶活性与这些疾病的关系,我们从这些卟啉症患者中表达了携带 His 标签的突变 CPOX,并在大肠杆菌中串联共表达携带 His 标签的突变 CPOX 和携带 HA 标签的正常 CPOX。含 His 标签的酶的纯化表明 His 酶与 HA 酶形成异二聚体,并且使用交联试剂的分析证实该酶是二聚体(∼70 kDa)。然后,我们表达了由野生型(wt)和酶的工程突变体或来自 HCP 患者的突变体组成的同型和异型二聚体。突变 CPOX 的单体形式没有显示任何活性,并且来自 HCP 突变的同源二聚体酶显示出低活性(<对照的 20%)。氨基酸 401-404 的一些突变与 harderoporphyrinogen 的大量积累有关,导致 protoporphyrinogen 的产生减少,而来自 harderoporphyria 患者的 K404E 则产生较少的 harderoporphyrinogen。来自 HCP 患者的 wt 和突变亚基的异二聚体显示出低 protoporphyrinogen 产生活性。这些结果表明,氨基酸从 R401 到 K404 的取代导致无论是突变同源二聚体还是含有正常和突变亚基的异二聚体的酶活性极低,并且与 HCP 疾病相关。